Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Early Results

Faculty Opinions recommendation of Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1147293.604446 ◽

2009 ◽

Author(s):

Florence Duffaud

Keyword(s):

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Early Results

Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000

10.1200/jco.2005.23.16_suppl.9009 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 9009-9009 ◽

Cited By ~ 21

Author(s):

R. P. Dematteo ◽

C. R. Antonescu ◽

V. Chadaram ◽

Y. N. You ◽

L. McCall ◽

...

Keyword(s):

High Risk ◽

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Complete Resection ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

The U.S

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.

10.1200/jco.2011.29.15_suppl.10057 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 10057-10057 ◽

Cited By ~ 1

Author(s):

D. Wang ◽

Q. Zhang ◽

C. D. Blanke ◽

G. D. Demetri ◽

M. C. Heinrich ◽

...

Keyword(s):

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Long Term Follow Up

ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with 18F-FDG PET and Correlation with Genotype and GLUT4 Expression

Journal of Nuclear Medicine ◽

10.2967/jnumed.111.094425 ◽

2012 ◽

Vol 53 (4) ◽

pp. 567-574 ◽

Cited By ~ 31

Author(s):

A. D. Van den Abbeele ◽

C. Gatsonis ◽

D. J. de Vries ◽

Y. Melenevsky ◽

A. Szot-Barnes ◽

...

Keyword(s):

Imatinib Mesylate ◽

Phase Ii ◽

Fdg Pet ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Glut4 Expression ◽

18F Fdg

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor harboring secondary mutation with exon 17: Interim report of a phase II trial.

10.1200/jco.2016.34.15_suppl.e22511 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e22511-e22511 ◽

Cited By ~ 1

Author(s):

Chun-Nan Yeh

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Secondary Mutation ◽

Efficacy And Safety ◽

Interim Report

Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate

Dermatology Online Journal ◽

10.5070/d3266049324 ◽

2020 ◽

Vol 26 (6) ◽

Author(s):

Hal A Lewis ◽

David Y Chen ◽

Ilana S Rosman ◽

Joel Picus ◽

Milan J Anadkat

Keyword(s):

Imatinib Mesylate ◽

Stromal Tumor ◽

Pemphigus Foliaceus ◽

Adjuvant Imatinib

Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan.

10.1200/jco.2010.28.15_suppl.10015 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 10015-10015 ◽

Cited By ~ 5

Author(s):

T. Nishida ◽

A. Sawaki ◽

T. Doi ◽

Y. Yamada ◽

Y. Komatsu ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Line Therapy ◽

Third Line Therapy ◽

Third Line

9413 Phase II trial of adjuvant imatinib mesylate after resection of localized, primary high risk gastrointestinal stromal tumour (GIST) in Japan

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)72001-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 594

Author(s):

T. Nishida ◽

T. Kanda ◽

N. Wada ◽

O. Kobayashi ◽

M. Yamamoto ◽

...

Keyword(s):

High Risk ◽

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Gastrointestinal Stromal Tumour ◽

Stromal Tumour ◽

Adjuvant Imatinib

Gastrointestinal stromal tumor of the cecum with disseminated omental and pancreatic lesions in a dog treated with surgical resection and adjuvant imatinib mesylate chemotherapy

Journal of Japan Veterinary Cancer Society ◽

10.12951/jvcs.2018-002 ◽

2020 ◽

Vol 9 (1) ◽

pp. 1-5

Author(s):

Hiroyuki Igarashi ◽

Kyoko Igarashi

Keyword(s):

Imatinib Mesylate ◽

Surgical Resection ◽

Stromal Tumor ◽

Adjuvant Imatinib

A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

Oncotarget ◽

10.18632/oncotarget.17310 ◽

2017 ◽

Vol 8 (27) ◽

pp. 44121-44130 ◽

Cited By ~ 20

Author(s):

Chun-Nan Yeh ◽

Ming-Huang Chen ◽

Yen-Yang Chen ◽

Ching-Yao Yang ◽

Chueh-Chuan Yen ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor